# HORIZON-Lung (NCT04818333)

> A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04818333
- Phase: PHASE1, PHASE2
- Status: UNKNOWN
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Conditions: Advanced Non-small Cell Lung Cancer
- Interventions: SHR-A1811
- Enrollment: 157
- Primary outcome: Phase 1:Incidence of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811
- Primary outcome: Phase 1:Severity of Adverse Events (AEs) by CTCAE v5.0 of SHR-A1811
- Primary outcome: Phase1: Maximum tolerated dose (MTD)
- Primary outcome: Phase 1: Recommended Phase 2 dose (RP2D)
- Primary outcome: Phase2:ObjectiveResponse Rate (ORR)

## Indexed commentary on HORIZON-Lung so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=horizon-lung-nct04818333